Mubritinib
Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.
primaryTopic
Mubritinib
Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.
has abstract
Mubritinib (TAK-165) is a prot ...... surfaced since December 2008.
@en
ATC prefix
CAS number
366017-09-6
FDA UNII code
V734AZP9BR
IUPAC name
1-(4-{4-[(2-{(E)-2-[4-(trifluo ...... henyl}butyl)-1H-1,2,3-triazole
@en
PubChem
thumbnail
Wikipage page ID
26,920,239
Wikipage revision ID
723,325,168
ChEMBL
ChemSpiderID
IUPHAR ligand
legal status
molecular weight
routes of administration
smiles
FCc1ccc\C=C\c2ncCOc3cccCCCCn4nncc4
hypernym
comment
Mubritinib (TAK-165) is a prot ...... surfaced since December 2008.
@en
label
Mubritinib
@en